Corcept Therapeutics Incorporated (CORT) Insider Robert S. Fishman Sells 8,000 Shares
Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $18.67, for a total value of $149,360.00. Following the transaction, the insider now directly owns 8,000 shares in the company, valued at approximately $149,360. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Corcept Therapeutics Incorporated (NASDAQ CORT) opened at $20.65 on Friday. The company has a market capitalization of $2,379.49, a price-to-earnings ratio of 71.21 and a beta of 1.89. Corcept Therapeutics Incorporated has a 12-month low of $6.70 and a 12-month high of $21.00.
Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). The business had revenue of $42.70 million during the quarter, compared to the consensus estimate of $41.64 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The business’s revenue was up 96.8% compared to the same quarter last year. During the same period last year, the company earned $0.02 EPS. equities analysts predict that Corcept Therapeutics Incorporated will post 0.47 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Corcept Therapeutics by 18.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,440,064 shares of the biotechnology company’s stock valued at $52,394,000 after acquiring an additional 689,554 shares during the last quarter. Renaissance Technologies LLC grew its position in Corcept Therapeutics by 44.4% in the 2nd quarter. Renaissance Technologies LLC now owns 2,683,400 shares of the biotechnology company’s stock valued at $31,664,000 after acquiring an additional 824,900 shares during the last quarter. State Street Corp grew its position in Corcept Therapeutics by 26.1% in the 2nd quarter. State Street Corp now owns 2,028,013 shares of the biotechnology company’s stock valued at $23,931,000 after acquiring an additional 420,139 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Corcept Therapeutics by 41.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,204,325 shares of the biotechnology company’s stock valued at $23,242,000 after acquiring an additional 355,006 shares during the last quarter. Finally, Prudential Financial Inc. grew its position in Corcept Therapeutics by 74.1% in the 3rd quarter. Prudential Financial Inc. now owns 1,102,483 shares of the biotechnology company’s stock valued at $21,278,000 after acquiring an additional 469,260 shares during the last quarter. 64.64% of the stock is currently owned by institutional investors.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.